What's Happening?
Pomerantz LLP has announced a class action lawsuit against ImmunityBio, Inc. following a warning letter from the U.S. Food and Drug Administration (FDA). The FDA's letter, dated March 13, 2026, criticized ImmunityBio for misleading promotions of its bladder-cancer
drug, Anktiva. The company's stock price fell significantly after the letter became public. Investors who purchased ImmunityBio securities during the class period have until May 26, 2026, to seek appointment as Lead Plaintiff in the lawsuit. The case will address allegations of securities fraud and other unlawful business practices by the company.
Why It's Important?
This lawsuit highlights the potential legal and financial repercussions for companies that engage in misleading promotional practices. The FDA's involvement underscores the importance of regulatory compliance in the pharmaceutical industry. For investors, the outcome of this class action could impact their financial recovery and influence future investment decisions. The case also serves as a reminder of the critical role that law firms like Pomerantz play in holding corporations accountable for securities fraud and protecting investor rights.
